LYON, France, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
The rest is here:
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2020
SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ansun Biopharma, Inc., a clinical stage biopharmaceutical company, today announced the company will present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference, taking place September 14-16. During the conference, Nancy Chang, Ph.D., chief executive officer of Ansun, will deliver a corporate update to potential investors registered for the meeting. The corporate update will cover recent and upcoming company milestones, as well as detail clinical progress of the company’s lead drug candidate, DAS181, a multi-mechanism recombinant sialidase protein being studied for its potential to treat patients with respiratory diseases, including influenza and parainfluenza, by preventing viral entry into respiratory epithelial cells. Ansun is also assessing DAS181 in patients with severe COVID-19 in Phase 2 studies.
Read the original post:
Ansun Biopharma to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Company announcement – No. 49 / 2020
Original post:
Zealand Pharma grants warrants and restricted share units under the employee warrant program and management long-term incentive program
WALTHAM, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Professor Eitan Kerem, M.D. has joined the Company as a Senior Consultant. Dr. Kerem will continue to advise on our cystic fibrosis program focusing on strategic leadership, cystic fibrosis medical safety review, and medical communications, as well as liaising with patient advocacy groups and regulatory authorities.
Excerpt from:
Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant
Accredited Cannabis Labs Support Cannabis Industry Certification Program Accredited Cannabis Labs Support Cannabis Industry Certification Program
See the original post:
Purity-IQ Partners with First North American Testing Labs
TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has launched a commercial evaluation in collaboration with Applied Spectral Imaging (ASI) California to assess the applicability of integrating GenASIs™, the ASI automated imaging and analysis solutions into TELO’s workflow.
Read more here:
Telo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with TELO Workflow
- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 -
Excerpt from:
Novan Provides Pipeline and Priority Development Programs Update
MENLO PARK, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced the appointment of Susan G. Kim as Chief Financial Officer, effective as of September 28, 2020.
Read this article:
Pacific Biosciences Announces New Chief Financial Officer
FORT LAUDERDALE, Fla., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that the China National Intellectual Property Administration ("CNIPA") issued patent 201680002365, titled “Distal Front End for Coordination Positioning of an Endoscope with a Suction Device.” The patent covers the method of mounting Motus GI’s proprietary sensing technology and enhanced suction systems with the distal end of a colonoscope. This patent further protects the Company’s flagship product – the Pure-Vu® System – in this key potential market.
Continue reading here:
Motus GI Expands Intellectual Property Portfolio with Chinese Patent for its Method to Mount the Pure-Vu® System on the End of a Colonoscope
Dr. James Woody’s leadership qualities and experience leading innovative pharmaceutical ventures and raising funds will power Enosi’s development of second-generation anti-TNF therapeutics for inflammatory autoimmune diseases and cancer.